Comprehensive diarrhoea control in Zambia

Dr Samu Dube MDG Health Alliance Round Table Discussion 30 April 2013 New York Samu.dube@arkonline.org











Why Target Diarrhea? A neglected childhood killer...

- Diarrhoea is one of the leading causes of deaths in the developing world, particularly for children, approximately 1.5 million related child deaths each year.
- Among infectious diseases, diarrhoea ranks as the third leading cause of both mortality and morbidity after respiratory infections and HIV/AIDS.
- Rotavirus is responsible for approximately 1/3 of U5 mortality due to diarrhea. This is entirely preventable.




...that has a devastating effect on Zambia's 2.4m children




Source: ARK International Analysis (2012)

Combating Diarrhoea




Our intervention focusses on key prevention and treatment methods...



Source: 'Scaling Up Diarrhea Prevention and Treatment Interventions: A Lives Saved Tools Analysis', Walker et al (2011); ARK International Analysis (2012)


...selected for their high effectiveness and low coverage in Zambia

• ARK has developed it's strategy for targeting Childhood Diarrhea by analysing the effectiveness of intervention and current coverage rates, and will currently administer four of the most impactful interventions for diarrhea in its Zambia programme.




Source: 'Scaling Up Diarrhea Prevention and Treatment Interventions: A Lives Saved Tools Analysis', Walker et al (2011); 'Transforming Diarrhea and Pneumonia Treatment: Developing Ambitious Solutions', BMGF, UNICEF, CHAI (2011).

PAED Interventions, Coverage by Programme Year				
	Baseline	Targets		
Intervention	2011	2012	2013	2014
	Pre-intervention	YR1	YR2	YR3
Hand washing	20%	23%	25%	27%
Rotavirus Vaccine	0%	84%	90%	90%
Exclusive Breast Feeding	35%	37%	43%	45%
ORS	53%	64%	70%	75%
Zinc for treatment	0%	20%	30%	40%




Expected PAED impact

We have input these estimates into the Lives Saved Tool (LiST Model) assuming a **3 year coverage** and output yield is 15% reduction in all cause postneonatal under 5 mortality



Targets: to reduce U5 diarrhoea related mortality by 50% and overall U5 mortality by 15%, averting over 2,850 deaths



Source: ARK International Analysis (2012)

Programme progress

- 82000 children vaccinated with first dose, 60000 fully immunised coverage rates
- 281/560 health workers trained on IMCI but over 400 trained on rotavirus vaccine
- Over 200 000 caregivers/families reached
- Unlocking value from the ORS/Zn supply chain
- Formative research for behavioural change interventions:
 - Awareness and subsequent increased uptake of Zn /ORS
 - Exclusive breastfeeding
 - Hand-washing with soap

PAED clinic and training facility



Housing a public paediatric clinic with 4 consulting rooms, an observation bay, satellite lab, ultrasonography, offices, a board room and a training hall

Lessons learnt and questions that need answers



Programme lessons

- Government commitment may be slow to come in , but don't move without their buy in
- Measuring what you are doing is a must if you are to scale up – separate program ACADEMIC which is measuring program impact
- Behavioural change components hard to program and therefore often an afterthought

 may lag behind – and yet we need evidence of what behavioural interventions need to be part of an optimal package
- Partnerships key in driving such projects beyond the program partners one needs a community of practise around an intervention
- Continuous improvement is needed. We have completed a mid term program review and are adjusting some program elements accordingly

ROTA VACCINE PROTECTS YOUR BABY AGAINST SEVERE DIARRHOEA

Take YOUR 6 WEEK old baby

for Rota Vaccine at

your nearest clinc


1 Ship

CIDRZ

ark

Questions than still need answers


- What have we learned about training of health care workers to treat and vaccinate?
 - Training is costly we need innovative ways for high quality training
- How does pneumo vaccine / amoxicillin compare with rota vaccine/ORS and zinc?
 - Perhaps it does, but bearing in mind the other is an antibiotic with different issues on resistance.
 ORS/Zn bundling is a challenge that needs separate
- What benefits does a comprehensive disease focused approach have? Is this the best way of addressing other health issues?
 - We are yet to see the results
- We have a complex partnership in place in Zambia has the diversity of players contributed to success or does it add management cost/time? How do you get the right people around the table?
 - You cant go it alone , but boundary analysis is crucial





Concluding Reflections

We choose not to wait and see what happens, rather we take courage in making decisions today that will positively influence what happens tomorrow. We are aware of the risks From such commitments; but staying back is simply not an option.



THANK YOU ZIKOMO

AMESEGNALEHU ASANTE SANA **BAIE DANKIE BEDANKT** BINOBODONDI DEUS PAGARAPUSUNKI DHANJABHAT DJERE DIEUFECHE DA **DZIEKUJEMY** GELETOMA HVALA INKOSI **KANIMAMBO KEALEBOHA KEAITUMETSE** HARTELIJK DANK! HVAL A **KHOBKHUN MAG** KÖSZÖNÖN MAHADSANIT MAZVITA **MEDASE** MERCI MISAOTRA ZIKOMO

MILLE GRAZIE **MWASHU** NAGODE NAMVERA NATONDI NDIYABULELA OBRIGADO KIITOS **OKUHEPA** PANDU REALEBOGA **SHUKRAN** SIYABONGA SOSONGO SPASIBA TATENDA TESEKKŰRLER TWATASHA TSE ZU TIN BA DEH TWATOTELA VIELEN DANK VILLMOLS MERCI YAQENYILEY